InMode Ltd.(INMD) Stock Research - Grey Stern Research

InMode Ltd. (INMD) Stock Analysis

$17.89 (1.65%)

INMD Financial Performance


Use the table below to view InMode Ltd.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $17.89 -
52 Week Low $16.44 -
52 Week High $44.78 -
Market Cap $1.5 Billion 15/15
Gross Margin 80% 4/15
Profit Margin 30% 1/15
EBITDA margin 23% 6/15
Q1 - 2024 Revenue $80.3 Million 15/15
Q1 - 2024 Earnings $23.7 Million 11/15
Q1 - 2024 Free Cash Flow $24.0 Million 8/15
Trailing 4 Quarters Revenue $466.3 Million 14/15
Trailing 4 Quarters Earnings $181.1 Million 10/15
Quarterly Earnings Growth -41% 13/15
Annual Earnings Growth 18% 9/15
Quarterly Revenue Growth -24% 15/15
Annual Revenue Growth -8% 14/15
Cash On Hand $120.9 Million 13/15
Short Term Debt $0 14/15
Long Term Debt $6.2 Million 15/15

InMode Ltd. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare InMode Ltd.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 8.36 11/15
PS 3.25 14/15
PB 1.86 14/15
PC 12.52 15/15
Liabilities to Equity 0.09 15/15
ROA 0.20 1/15
ROE 0.22 3/15
Current Ratio 11.69 1/15
Quick Ratio 10.10 1/15
Long Term Debt to Equity 0.01 15/15
Debt to Equity 0.01 15/15
Burn Rate -5.16 11/15
Cash to Cap 0.08 1/15
CCR 1.01 4/15
EV to EBITDA 76.63 9/15
EV to Revenue 3.00 15/15

Company Details

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

CEO: Mr. Moshe Mizrahy

Website: https://www.inmodemd.com

Address: Tavor Building, Sha'ar Yokneam, Pob 533 YOKNEAM,

Exchange: NASDAQ Global Select

Industry: Medical Devices

InMode Ltd. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to InMode Ltd.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Boston Scientific Corporation BSX $110.1 Billion
Abbott Laboratories ABT $183.1 Billion
Medtronic plc MDT $100.9 Billion
Zimmer Biomet Holdings, Inc. ZBH $22.9 Billion
Tandem Diabetes Care, Inc. TNDM $2.6 Billion
DexCom, Inc. DXCM $25.5 Billion
Edwards Lifesciences Corporation EW $37.6 Billion
Stryker Corporation SYK $126.3 Billion
Insulet Corporation PODD $13.5 Billion
Align Technology, Inc. ALGN $16.6 Billion
Inspire Medical Systems, Inc. INSP $3.7 Billion
ShockWave Medical, Inc. SWAV $12.6 Billion
TransMedics Group, Inc. TMDX $4.6 Billion
Inari Medical, Inc. NARI $3.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
INMD Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 80.3 Million $23.7 Million
Q4 2023 $ 126.8 Million $55.2 Million
Q3 2023 $ 123.1 Million $46.5 Million
Q2 2023 $ 136.1 Million $55.7 Million
Q1 2023 $ 106.1 Million $40.5 Million
Q4 2022 $ 133.6 Million $37.7 Million
Q3 2022 $ 121.2 Million $48.8 Million
Q2 2022 $ 113.5 Million $44.0 Million

View All

INMD Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $120.9 Million $891.7 Million $6.2 Million $815.4 Million
Q4 2023 $144.4 Million $863.3 Million $9.0 Million $787.4 Million
Q3 2023 $133.7 Million $793.5 Million $3.6 Million $723.5 Million
Q2 2023 $159.9 Million $734.1 Million $3.6 Million $666.2 Million
Q1 2023 $93.0 Million $669.6 Million $3.5 Million $603.0 Million
Q4 2022 $97.5 Million $644.4 Million $5.0 Million $554.6 Million
Q3 2022 $77.0 Million $579.0 Million $3.7 Million $508.3 Million
Q2 2022 $88.4 Million $523.2 Million $3.7 Million $452.8 Million

View All

INMD Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $24.0 Million -$112,000 -$23.5 Million
Q4 2023 $61.2 Million -$21,000 $10.7 Million
Q3 2023 $41.3 Million -$149,000 -$26.1 Million
Q2 2023 $52.8 Million -$194,000 $66.9 Million
Q1 2023 $20.8 Million -$341,000 -$4.6 Million
Q4 2022 $56.8 Million -$328,000 $20.5 Million
Q3 2022 $45.2 Million -$387,000 -$11.4 Million
Q2 2022 $46.4 Million -$561,000 $43.7 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions